Áttétes emlőrák: ki dolgozik rajta

Intézményenként egy kártya. Szűrhetsz célpontra, országra, vagy csak az EU-13 (Horizon Europe felzárkózó) országok intézményeire.

• Minden célpont
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• PARP 7
• BRCA2 2
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

Az EU-13 szűrő, nem rangsor: csak szűkíti a listát.

93+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· UNICANCER· Frissítve: 2026. okt. 14.

  “poor accrual”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

  NCT04315233· University of Utah· Frissítve: 2026. szept. 4.

  “No accrual in one year”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

  NCT03439046· Novartis Pharmaceuticals· Frissítve: 2026. júl. 10.

  “Novartis terminated the trial early because the collected data were sufficient to perform the analysis stated for the primary endpoint.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

  NCT06585969· Danish Breast Cancer Cooperative Group· Frissítve: 2026. febr. 12.

  “Lack of funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of PF-06873600 in People With Cancer

  NCT03519178· Pfizer· Frissítve: 2025. nov. 14.

  “Per business decision, but not due to safety concerns or regulatory request.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  NCT04557449· Pfizer· Forrás

• BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer

  NCT07492641· BeOne Medicines I GmbH· Forrás

• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Eli Lilly and Company· Forrás

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Hoffmann-La Roche· Forrás

• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· AstraZeneca· Forrás

• A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

  NCT06247995· Novartis Pharmaceuticals· Forrás

• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Pfizer· Forrás

• Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.

  NCT06417801· AstraZeneca· Forrás

• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Pfizer· Forrás

• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

  NCT06120283· BeOne Medicines· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 21
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 63
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 70
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 57
• Genome-Wide Association Study 1

• Impact of Transfer Learning and Model Capacity on Patch-Level Metastasis Detection Across Training Data Regimes.

  Stud Health Technol Inform, 2026. szept.

• A multimodal cross-temporal fusion system for complementary evaluation of neoadjuvant chemotherapy in breast cancer.

  Eur J Radiol, 2026. szept.

• Deep-learning-enabled multi-omics analyses for prediction of future metastasis in cancer.

  Nat Commun, 2026. aug.

• Integrating MRI radiomics and deep learning for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study.

  BMC Med Imaging, 2026. júl.

• A Multimodal Multitask Deep Learning Model Based on Ultrasound RF Signals for Joint Assessment of Breast Masses and Axillary Lymph Nodes Status.

  Ultrasound Med Biol, 2026. júl.

• Establishing a Multimodal Model for Predicting Lymphovascular Invasion in Breast Cancer Using Deep Transfer Learning Based on Ultrasound and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

  Oncol Res Treat, 2026. júl.

• An intelligent MRI-based all-in-one diagnostic strategy for axillary lymph node status in breast cancer.

  Nat Commun, 2026. jún.

• Assessing the performance of deep learning and hand-crafted radiomics models using MRI and ultrasound in predicting axillary lymph node status in breast cancer: a systematic review and meta-analysis.

  Eur Radiol, 2026. jún.

• Deep learning model for noninvasive prediction of Ki-67 expression and prognostic stratification in breast cancer: a multicenter retrospective study.

  Eur Radiol, 2026. máj.

• Accuracy of Deep Learning for Detecting Axillary Lymph Node Metastasis in Breast Cancer: Systematic Review and Meta-Analysis.

  J Med Internet Res, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.